Systemic Screening for Node-positive Breast Cancer
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer
Recruiting
Phase 2
Interventional Study
Breast Cancer
Node-positive Breast Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 120 (estimated)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Other
Who this trial is looking for
This trial is looking for women with node-positive breast cancer who have completed treatment. Participants will undergo CT scans to check for the spread of cancer over about 6 months.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with breast cancer.
- I am 18 years or older.
- I have completed at least 8 weeks of neoadjuvant chemotherapy.
- I have a life expectancy of at least 6 months.
- I understand the study procedures and will sign consent.
- I can comply with all study procedures.
You may not be able to join if
- I have a prior diagnosis of systemic metastases.
- I have a history of other cancers that were not treated at least 2 years ago.
- I cannot receive CT contrast dye.
- I have chronic kidney disease stage IV or V.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The purpose of the study is to determine the frequency of systemic metastasis in node positive breast cancer following chemotherapy and surgery. Participants will be asked to spend about 6 months in this study. Participants will undergo a computed tomography (CT) screening of the thorax, abdomen, and pelvis at baseline prior to adjuvant radiation therapy and another CT screening of the thorax, abd…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histologic diagnosis of breast cancer with documentation of ER/PR/HER2 status.
* HR+ will be defined as ER and/or PR ≥ 10%. To be classified as HER2+ disease, overexpression of HER2 by either IHC or in-situ hybridization is necessary as defined by the ASCO / CAP Guidelines27. …
Contacts